Ionis Pharmaceuticals, Inc. IONS Income Statement

Ionis pharmaceuticals, inc. (IONS)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10	Sep'09	Jun'09
Revenue:
Revenue
133,367	493,680	167,892	163,813	297,214	192,113	145,395	117,747	144,419	167,792	118,314	112,273	115,800	186,505	110,927	38,470	36,874	51,571	49,121	120,428	62,583	84,861	44,063	57,076	28,161	42,248	23,585	38,092	43,360	19,873	11,601	47,340	23,235	32,403	20,713	24,823	21,147	26,420	28,624	23,503	29,926	26,771	30,992
Expenses:
Cost of products sold
2,548	1,012	967	1,364	1,041	1,820	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sa
116,952	148,740	104,366	106,165	106,417	113,452	95,255	101,830	104,067	128,286	80,214	83,506	82,638	101,152	84,631	77,573	80,964	101,330	88,508	68,007	64,447	67,953	61,086	59,264	53,448	57,430	45,660	42,631	38,312	42,758	36,551	40,435	38,714	47,219	39,924	36,009	34,245	39,333	34,716	39,124	31,987	33,832	32,146
Selling, general and administrative
74,994	83,276	60,036	75,111	68,221	66,059	68,712	66,198	43,653	45,706	26,788	22,317	13,677	18,042	10,188	9,824	10,562	13,181	8,751	7,775	7,466	6,828	4,470	4,462	4,380	4,676	3,430	3,389	3,423	3,234	3,096	3,209	2,976	3,800	3,105	2,874	3,010	2,944	2,855	3,051	2,819	3,335	3,673
Total operating expenses
194,494	233,028	165,369	182,640	175,679	181,331	163,967	168,028	147,720	173,992	107,002	105,823	96,315	119,194	94,819	87,397	91,526	114,511	97,259	75,782	71,913	74,781	65,556	63,726	57,828	62,106	49,090	46,020	41,735	45,992	39,647	43,644	41,690	51,019	43,029	38,883	37,255	42,277	37,571	42,175	34,806	37,167	35,819
Income (loss) from operations
-61,127	260,652	2,523	-18,827	121,535	10,782	-18,572	-50,281	-3,301	-6,200	11,312	6,450	19,485	67,311	16,108	-48,927	-54,652	-62,940	-48,138	44,646	-9,330	10,080	-21,493	-6,650	-29,667	-19,858	-25,505	-7,928	1,625	-26,119	-28,046	3,696	-18,455	-18,616	-22,316	-14,060	-16,108	-15,857	-8,947	-18,672	-4,880	-10,396	-4,827
Other income (expense):
Equity in net loss of Regulus Therapeutics Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-267	0	-163	-976	-1,279	-386	-1,033	-856	-521	-930	-3,942	-1,486	-	-
Investment income
10,479	13,192	13,136	13,735	12,142	11,477	9,963	5,137	3,610	623	2,811	2,465	2,280	1,560	989	1,466	1,457	1,230	1,384	918	845	679	675	671	657	686	434	589	376	359	408	477	600	518	575	616	705	780	776	859	955	1,430	1,678
Interest expense
10,990	13,365	12,002	11,802	11,599	11,456	11,282	11,113	10,938	10,786	10,825	11,778	11,363	9,934	9,746	9,625	9,490	9,351	9,233	9,127	9,021	7,307	4,998	4,961	4,943	4,885	4,867	4,808	4,795	4,817	5,937	5,219	5,179	5,107	4,773	3,437	3,415	3,396	3,338	3,261	3,237	3,185	3,155
Gain on investments, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,116	3	-260	397	305	175	840	1,058	1,446	0	2	17	4,448	18	34	-318	448	-15	-136	-1,010	123	2,612
Gain on investment in Regulus Therapeutics Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20,211	-	-	-	535	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Difference between the purchase price of the facility and the carrying value of our financing liability at the time of the purchase.
-	-	-	-	-	-	-	-	-	-	-7,689	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on early retirement of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4,770	-	-	-	-	-	-	-	-	-	-	-	-
Other expenses
-99	-354	-140	-45	-147	-37	-22	45	-168	-2,845	-2,141	0	1,438	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income (loss) before income tax benefit (expense)
-61,737	238,260	3,517	-16,939	121,931	10,766	-19,913	-56,212	-10,797	-16,332	-6,532	-2,863	8,964	54,954	7,351	-57,086	-62,685	-71,061	-35,776	36,437	-17,506	15,643	-25,278	-11,200	-33,556	-23,752	-29,763	-11,307	-1,736	-11,042	-38,345	-1,207	-23,993	-20,036	-26,882	-17,880	-19,992	-13,895	-12,454	-25,152	-9,658	-12,028	-3,692
Income tax benefit (expense)
-3,300	34,307	-14,900	-6,900	31,000	-292,056	500	400	15	-7,163	961	222	0	2,933	0	-231	232	372	0	789	-789	-15,410	1,398	881	-2,276	524	-5,193	-1,181	-64	-8,405	-706	0	2	0	0	9	2	-	-	2	-	724	-11
Net loss from continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-12,752	-3,681
Gain on sale of Ibis Biosciences, Inc., net of tax
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	34	94
Net income from discontinued operations, net of tax
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	34	94
Net income (loss)
-58,480	203,958	18,432	-10,012	90,884	302,732	-20,365	-56,570	-10,812	-9,169	-7,493	-3,085	8,964	-	7,351	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-12,718	-3,587
Net (income) loss attributable to noncontrolling interest in Akcea Therapeutics, Inc.
-10,254	19,543	-7,732	-9,136	6,441	-17,343	-15,806	-16,215	-9,392	-6,247	-4,882	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,136	-857
Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders
-48,226	184,416	26,163	-876	84,443	320,075	-4,559	-40,355	-1,420	-2,922	-2,611	-3,085	8,964	52,021	7,351	-56,855	-62,917	-71,433	-35,776	35,648	-16,717	31,053	-26,676	-12,081	-31,280	-24,276	-24,570	-10,126	-1,672	-2,637	-37,639	-1,207	-23,995	-20,036	-26,882	-17,889	-19,994	-13,985	-12,454	-25,154	-9,658	-11,582	-2,730
Basic and diluted net loss per share (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.47	-	-	-	-	-0.14	-	-0.23	-	-0.27	-0.23	-0.21	-0.09	-0.02	-0.03	-0.37	-0.01	-0.24	-0.20	-0.27	-0.18	-0.20	-	-	-	-	-	-
Shares used in computing basic and diluted net loss per share (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	120,798	-	-	-	-	118,948	-	117,811	-	117,128	116,331	115,263	108,539	101,875	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss from continuing operations attributable to Isis Pharmaceuticals, Inc. common stockholders, Basic (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.12	-0.03
Basic net income per share (in dollars per share)
-0.35	1.31	0.19	-0.01	0.63	2.42	-0.03	-0.29	-0.01	0.12	-0.02	-0.02	0.07	-	0.06	-	-0.52	-	-0.30	0.30	-	-	-	-0.10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.13	-0.25	-0.10	-0.12	-0.03
Shares used in computing basic net income (loss) per share (in shares)
139,429	140,612	140,551	140,247	138,582	137,892	137,346	128,712	125,330	124,844	124,370	123,989	122,861	-	120,989	-	120,598	-	119,979	119,742	-	-	-	117,588	-	-	-	-	-	-	100,680	100,213	100,157	99,766	99,687	99,602	99,569	99,272	99,196	99,091	99,013	98,320	98,116
Net loss from continuing operations attributable to Isis Pharmaceuticals, Inc. common stockholders, Diluted (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.12	-0.03
Diluted net income per share (in dollars per share)
-0.35	1.29	0.18	-0.01	0.62	2.40	-0.03	-0.29	-0.01	0.12	-0.02	-0.02	0.07	-	0.06	-	-0.52	-	-0.30	0.29	-	-	-	-0.10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.13	-0.25	-0.10	-0.12	-0.03
Shares used in computing diluted net income (loss) per share (in shares)
139,429	146,296	143,408	140,247	141,537	144,836	137,346	128,712	125,330	131,061	124,370	123,989	124,972	-	123,378	-	120,598	-	119,979	127,779	-	-	-	117,588	-	-	-	-	-	-	100,680	100,213	100,157	99,766	99,687	99,602	99,569	99,272	99,196	99,091	99,013	98,320	98,116
Commercial [Member]
Revenue
83,961	100,364	95,699	88,299	68,088	72,945	82,756	57,198	42,023	53,908	34,617	23,688	7,801	3,078	2,014	16,015	1,660	679	203	770	691	2,323	265	448	8,611	598	327	477	1,689	3,543	474	200	1,417	721	524	518	1,133	983	839	2,360	1,370	809	224
Royalty revenues from the sale of SPINRAZA (nusinersen).
Revenue
66,008	81,107	81,672	70,502	59,711	70,186	70,010	56,653	41,081	52,073	32,890	22,366	5,211	883	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue from the sale of TEGSEDI (inotersen).
Revenue
15,159	13,689	11,945	9,865	6,754	2,237	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue from license fees and other royalties, excluding royalties from the sale of SPINRAZA.
Revenue
2,794	5,568	2,082	7,932	1,623	522	12,746	545	942	1,835	1,727	1,322	2,590	2,195	2,014	16,015	1,660	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue from research and development services performed under a collaboration agreement.
Revenue
49,406	393,316	72,193	75,514	229,126	119,168	62,639	60,549	102,396	113,884	83,697	88,585	107,999	183,427	108,913	22,455	35,214	50,892	48,918	119,658	61,892	82,538	43,798	56,628	19,550	41,650	23,258	37,615	41,671	16,330	11,127	47,140	21,818	31,682	20,189	24,305	20,014	25,437	27,785	21,143	28,556	25,962	30,768